License and Asset Purchase Agreements - Additional Information - Antengene License Agreement (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2020	May 23, 2018
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty revenue recognized	$ 146,033	$ 157,074	$ 209,819
Antengene Therapeutics [Member] | Royalty [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Royalty revenue recognized	$ 1,500	$ 3,800	800
Antengene Therapeutics [Member] | Government Research Grant Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Initial transaction				$ 11,700
License agreement termination prior notice period	180 days
License agreement termination description	Agreement may be terminated earlier by (i) either party for breach of the Amended Antengene Agreement by the other party or in the event of the insolvency or bankruptcy of the other party, (ii) Antengene on a product-by-product basis for certain safety reasons or on a product-by-product, country-by-country basis for any reason with 180 days prior notice or (iii) us in the event Antengene challenges or assists with a challenge to certain of our patent rights.
Antengene Therapeutics [Member] | Eltanexor [Member] | Government Research Grant Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Performance obligations			$ 300
Up-front Payment Arrangement [Member] | Antengene Therapeutics [Member] | Government Research Grant Agreement [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Initial transaction					$ 11,700	$ 11,700